Data gathered: January 23
AI Stock Analysis - Madrigal Pharmaceuticals (MDGL)
Analysis generated June 25, 2024. Powered by Chat GPT.
Madrigal Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of cardiovascular and metabolic diseases. The company leverages its expertise in small molecule drug discovery to develop novel treatments targeting unmet medical needs. Madrigal's primary mission is to develop therapeutic candidates that can transform the standard of care for diseases with serious health impacts.
Stock Alerts - Madrigal Pharmaceuticals (MDGL)
 |
Madrigal Pharmaceuticals | January 23 Price is up by 5.3% in the last 24h. |
|
Madrigal Pharmaceuticals | January 22 Price is up by 5.7% in the last 24h. |
|
Madrigal Pharmaceuticals | January 21 Employee Rating is down by 5.1% over the last month. |
|
Madrigal Pharmaceuticals | January 18 Insider Alert: Kelley Shannon T is selling shares |
Alternative Data for Madrigal Pharmaceuticals
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 41 | Sign up | Sign up | Sign up |
| Sentiment | 96 | Sign up | Sign up | Sign up |
| Webpage traffic | 17,000 | Sign up | Sign up | Sign up |
| Employee Rating | 74 | Sign up | Sign up | Sign up |
| Google Trends | 23 | Sign up | Sign up | Sign up |
| Patents | 23 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 1 | Sign up | Sign up | Sign up |
| Facebook Followers | 26 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 21 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 6,301 | Sign up | Sign up | Sign up |
| Twitter Followers | 1,467 | Sign up | Sign up | Sign up |
| Twitter Mentions | 16 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 114 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Business Outlook | 100 | Sign up | Sign up | Sign up |
| Linkedin Employees | 559 | Sign up | Sign up | Sign up |
About Madrigal Pharmaceuticals
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States.
| Price | $340.14 |
| Target Price | Sign up |
| Volume | 662,730 |
| Market Cap | $6.7B |
| Year Range | $202.48 - $354.85 |
| Dividend Yield | 0% |
| Analyst Rating | 86% buy |
| Industry | Biotechnology |
In the news
 |
Equities Analysts Offer Predictions for MDGL FY2025 EarningsJanuary 22 - ETF Daily News |
|
Research Analysts Offer Predictions for MDGL FY2024 EarningsJanuary 18 - ETF Daily News |
 |
Madrigal Pharmaceuticals Rezdiffra Vies For Blockbuster Status In MASHJanuary 18 - SeekingAlpha |
 |
Madrigal Pharmaceuticals general counsel sells $75,734 in stockJanuary 17 - Investing.com |
 |
Madrigal Pharmaceuticals executive sells shares worth $120,847January 17 - Investing.com |
 |
Madrigal Pharmaceuticals exec sells $461,789 in stockJanuary 17 - Investing.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 58M | 108M | -49M | -107M | -116M | -4.920 |
| Q2 '24 | 11M | 105M | -94M | -152M | -162M | -7.100 |
| Q1 '24 | 0 | 81M | -81M | -148M | -152M | -7.380 |
| Q4 '23 | 0 | 47M | -47M | -112M | -117M | -5.680 |
| Q3 '23 | 0 | 28M | -31M | -99M | -99M | -5.340 |
Insider Transactions View All
| Waltermire Robert E. filed to sell 5,058 shares at $273.4. January 17 '25 |
| Kelley Shannon T filed to sell 7,705 shares at $273.4. January 17 '25 |
| Taub Rebecca filed to sell 457,310 shares at $273.4. January 17 '25 |
| CRAVES FRED B filed to sell 11,000 shares at $315.9. December 5 '24 |
| CRAVES FRED B filed to sell 11,520 shares at $315.2. December 5 '24 |
Similar companies
Read more about Madrigal Pharmaceuticals (MDGL) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, business outlook & linkedin employees.
What is the Market Cap of Madrigal Pharmaceuticals?
The Market Cap of Madrigal Pharmaceuticals is $6.7B.
What is the current stock price of Madrigal Pharmaceuticals?
Currently, the price of one share of Madrigal Pharmaceuticals stock is $340.14.
How can I analyze the MDGL stock price chart for investment decisions?
The MDGL stock price chart above provides a comprehensive visual representation of Madrigal Pharmaceuticals' stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Madrigal Pharmaceuticals shares. Our platform offers an up-to-date MDGL stock price chart, along with technical data analysis and alternative data insights.
Does MDGL offer dividends to its shareholders?
As of our latest update, Madrigal Pharmaceuticals (MDGL) does not offer dividends to its shareholders. Investors interested in Madrigal Pharmaceuticals should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Madrigal Pharmaceuticals?
Some of the similar stocks of Madrigal Pharmaceuticals are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.